Maxygen

From WikiCover

Jump to: navigation, search

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. They look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Their lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in their pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. They believe this advantage translates to a greater chance of successfully bringing important new drugs to market.

Website: http://www.maxygen.com/

Name (required):

Comment:

Retrieved from "http://www.wikicover.com/Maxygen"